At the time of writing, Ocular Therapeutix Inc [OCUL] stock is trading at $9.70, up 2.75%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The OCUL shares have gain 4.41% over the last week, with a monthly amount glided 27.97%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 11, March 2024, Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results. In a post published today on Yahoo Finance, Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care.
From an analyst’s perspective:
Ocular Therapeutix Inc [NASDAQ: OCUL] stock has seen the most recent analyst activity on February 09, 2024, when BofA Securities initiated its Buy rating and assigned the stock a price target of $15. Previously, Robert W. Baird started tracking the stock with Outperform rating on April 21, 2023, and set its price target to $18. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $17 on August 10, 2021. H.C. Wainwright downgraded its rating to a Neutral. Berenberg started tracking with a Buy rating for this stock on December 17, 2020, and assigned it a price target of $27. In a note dated November 13, 2020, Raymond James reiterated an Strong Buy rating on this stock and boosted its target price from $15 to $25.
For the past year, the stock price of Ocular Therapeutix Inc fluctuated between $2.00 and $11.31. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $9.70 at the most recent close of the market. An investor can expect a potential return of 3.09% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
According to Ocular Therapeutix Inc [NASDAQ:OCUL], the company’s sales were 58.44M for trailing twelve months, which represents an 5.16% jump. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -1.41%, Pretax Profit Margin comes in at -1.38%, and Net Profit Margin reading is -1.49%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -3.11 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.39 points at the first support level, and at 9.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.86, and for the 2nd resistance point, it is at 10.03.
Ocular Therapeutix Inc [OCUL] reported earnings per share of -$0.35 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.3/share, meaning a difference of -$0.05 and a surprise factor of -16.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.01 per share as compared to estimates of -$0.29 per share, a difference of $0.28 representing a surprise of 96.60%.
Ratios To Look Out For
It is important to note that Ocular Therapeutix Inc [NASDAQ:OCUL] has a current ratio of 6.66. Also, the Quick Ratio is 6.59, while the Cash Ratio stands at 5.62. Considering the valuation of this stock, the price to sales ratio is 24.67, the price to book ratio is 12.24.
Transactions by insiders
Recent insider trading involved SUMMER ROAD LLC, 10% Owner, that happened on Feb 26 ’24 when 0.93 million shares were purchased. President and CEO, Mattessich Antony C. completed a deal on Jan 31 ’24 to sell 18338.0 shares. Meanwhile, Chief Medical Officer Ozden Rabia Gurses sold 7764.0 shares on Jan 31 ’24.
